Neubase Therapeutics Stock Total Debt
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
NeuBase Therapeutics fundamentals help investors to digest information that contributes to NeuBase Therapeutics' financial success or failures. It also enables traders to predict the movement of NeuBase Stock. The fundamental analysis module provides a way to measure NeuBase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeuBase Therapeutics stock.
NeuBase |
NeuBase Therapeutics Company Total Debt Analysis
NeuBase Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current NeuBase Therapeutics Total Debt | 6 M |
Most of NeuBase Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeuBase Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, NeuBase Therapeutics has a Total Debt of 6 M. This is 99.78% lower than that of the Biotechnology sector and 98.15% lower than that of the Health Care industry. The total debt for all United States stocks is 99.89% higher than that of the company.
NeuBase Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeuBase Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeuBase Therapeutics could also be used in its relative valuation, which is a method of valuing NeuBase Therapeutics by comparing valuation metrics of similar companies.NeuBase Therapeutics is currently under evaluation in total debt category among its peers.
NeuBase Fundamentals
| Return On Equity | -0.93 | |||
| Return On Asset | -0.43 | |||
| Current Valuation | (5.83 M) | |||
| Shares Outstanding | 3.75 M | |||
| Shares Owned By Insiders | 13.37 % | |||
| Shares Owned By Institutions | 12.68 % | |||
| Number Of Shares Shorted | 15.57 K | |||
| Price To Earning | (4.17) X | |||
| Price To Book | 0.18 X | |||
| EBITDA | (32.49 M) | |||
| Net Income | (33.78 M) | |||
| Cash And Equivalents | 29.85 M | |||
| Cash Per Share | 0.93 X | |||
| Total Debt | 6 M | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 7.53 X | |||
| Book Value Per Share | 2.45 X | |||
| Cash Flow From Operations | (29.01 M) | |||
| Short Ratio | 0.24 X | |||
| Earnings Per Share | (18.60) X | |||
| Price To Earnings To Growth | (0.07) X | |||
| Target Price | 140.0 | |||
| Number Of Employees | 37 | |||
| Beta | 0.95 | |||
| Market Capitalization | 1.42 M | |||
| Total Asset | 32.69 M | |||
| Retained Earnings | (102.74 M) | |||
| Working Capital | 20.48 M | |||
| Current Asset | 4.14 M | |||
| Current Liabilities | 1.6 M | |||
| Net Asset | 32.69 M |
About NeuBase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeuBase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeuBase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeuBase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |